Stock Research for ALKS

ALKS

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

ALKS Stock Chart & Research Data

The ALKS chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ALKS chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ALKS Due diligence Resources & Stock Charts

The ALKS stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ALKS Detailed Price Forecast - CNN Money CNN View ALKS Detailed Summary - Google Finance
Yahoo View ALKS Detailed Summary - Yahoo! Finance Zacks View ALKS Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View ALKS Trends & Analysis - Trade-Ideas Barrons View ALKS Major Holders - Barrons
NASDAQ View ALKS Call Transcripts - NASDAQ Seeking View ALKS Breaking News & Analysis - Seeking Alpha
Spotlight View ALKS Annual Report - CompanySpotlight.com OTC Report View ALKS OTC Short Report - OTCShortReport.com
TradeKing View ALKS Fundamentals - TradeKing Charts View ALKS SEC Filings - Bar Chart
WSJ View Historical Prices for ALKS - The WSJ Morningstar View Performance/Total Return for ALKS - Morningstar
MarketWatch View the Analyst Estimates for ALKS - MarketWatch CNBC View the Earnings History for ALKS - CNBC
StockMarketWatch View the ALKS Earnings - StockMarketWatch MacroAxis View ALKS Buy or Sell Recommendations - MacroAxis
Bullish View the ALKS Bullish Patterns - American Bulls Short Pains View ALKS Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View ALKS Stock Mentions - StockTwits PennyStocks View ALKS Stock Mentions - PennyStockTweets
Twitter View ALKS Stock Mentions - Twitter Invest Hub View ALKS Investment Forum News - Investor Hub
Yahoo View ALKS Stock Mentions - Yahoo! Message Board Seeking Alpha View ALKS Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for ALKS - SECform4.com Insider Cow View Insider Transactions for ALKS - Insider Cow
CNBC View ALKS Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ALKS - OTC Markets
Yahoo View Insider Transactions for ALKS - Yahoo! Finance NASDAQ View Institutional Holdings for ALKS - NASDAQ


Stock Charts

FinViz View ALKS Stock Insight & Charts - FinViz.com StockCharts View ALKS Investment Charts - StockCharts.com
BarChart View ALKS Stock Overview & Charts - BarChart Trading View View ALKS User Generated Charts - Trading View




Latest Financial News for ALKS


Clovis (CLVS) Q2 Earnings & Sales Lag Estimates, Shares Down
Posted on Friday August 02, 2019

Clovis (CLVS) reports dismal second-quarter 2019 results. The company provides lower-than-expected guidance for product sales in 2019.


Biotech Stock Roundup: Celgene, Amgen, Gilead Impress in Q2, Other Pipeline Updates
Posted on Wednesday July 31, 2019

Impressive second-quarter results by most biotech bigwigs are the key highlights of the week. Most companies also increase their annual guidance.


Biogen Hedged Its Bet and Won Big
Posted on Tuesday July 30, 2019

The biotech had $4.3 billion in sales at risk.


Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared to Dimethyl Fumarate in Patients with Multiple Sclerosis
Posted on Tuesday July 30, 2019

DUBLIN and CAMBRIDGE, Mass., July 30, 2019 /PRNewswire/ -- Alkermes plc (ALKS) and Biogen Inc. (BIIB) today announced positive topline results from EVOLVE-MS-2, a large, randomized, double-blind, five-week, Phase 3 study of diroximel fumarate, an investigational, novel oral fumarate with a distinct chemical structure, for relapsing-remitting multiple sclerosis (RRMS), compared to TECFIDERA® (dimethyl fumarate). Diroximel fumarate was statistically superior to dimethyl fumarate on the study's pre-specified primary endpoint, with patients treated with diroximel fumarate self-reporting significantly fewer days of key gastrointestinal (GI) symptoms with intensity scores ≥2 on the Individual Gastrointestinal Symptom and Impact Scale (IGISIS), as compared to dimethyl fumarate (p = 0.0003).


Stock Market & Investing Books

Enter a stock symbol to view the stock details.